Cargando…
Risk Stratification in Oral Cancer: A Novel Approach
BACKGROUND: Oral squamous cell carcinoma (OSCC) is a common head and neck cancer with high morbidity and mortality. Currently, treatment decisions are guided by TNM staging, which omits important negative prognosticators such as lymphovascular invasion, perineural invasion (PNI), and histologic diff...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301677/ https://www.ncbi.nlm.nih.gov/pubmed/35875164 http://dx.doi.org/10.3389/fonc.2022.836803 |
_version_ | 1784751469882245120 |
---|---|
author | Tu, Irene Wen-Hui Shannon, Nicholas Brian Thankappan, Krishnakumar Balasubramanian, Deepak Pillai, Vijay Shetty, Vivek Rangappa, Vidyabhushan Chandrasekhar, Naveen Hedne Kekatpure, Vikram Kuriakose, Moni Abraham Krishnamurthy, Arvind Mitra, Arun Pattatheyil, Arun Jain, Prateek Iyer, Subramania Subramaniam, Narayana Iyer, N. Gopalakrishna |
author_facet | Tu, Irene Wen-Hui Shannon, Nicholas Brian Thankappan, Krishnakumar Balasubramanian, Deepak Pillai, Vijay Shetty, Vivek Rangappa, Vidyabhushan Chandrasekhar, Naveen Hedne Kekatpure, Vikram Kuriakose, Moni Abraham Krishnamurthy, Arvind Mitra, Arun Pattatheyil, Arun Jain, Prateek Iyer, Subramania Subramaniam, Narayana Iyer, N. Gopalakrishna |
author_sort | Tu, Irene Wen-Hui |
collection | PubMed |
description | BACKGROUND: Oral squamous cell carcinoma (OSCC) is a common head and neck cancer with high morbidity and mortality. Currently, treatment decisions are guided by TNM staging, which omits important negative prognosticators such as lymphovascular invasion, perineural invasion (PNI), and histologic differentiation. We proposed nomogram models based on adverse pathological features to identify candidates suitable for treatment escalation within each risk group according to the National Comprehensive Cancer Network (NCCN) guidelines. METHODS: Anonymized clinicopathologic data of OSCC patients from 5 tertiary healthcare institutions in Asia were divided into 3 risk groups according to the NCCN guidelines. Within each risk group, nomograms were built to predict overall survival based on histologic differentiation, histologic margin involvement, depth of invasion (DOI), extranodal extension, PNI, lymphovascular, and bone invasion. Nomograms were internally validated with precision–recall analysis and the Kaplan–Meier survival analysis. RESULTS: Low-risk patients with positive pathological nodal involvement and/or positive PNI should be considered for adjuvant radiotherapy. Intermediate-risk patients with gross bone invasion may benefit from concurrent chemotherapy. High-risk patients with positive margins, high DOI, and a high composite score of histologic differentiation, PNI, and the American Joint Committee on Cancer (AJCC) 8th edition T staging should be considered for treatment escalation to experimental therapies in clinical trials. CONCLUSION: Nomograms built based on prognostic adverse pathological features can be used within each NCCN risk group to fine-tune treatment decisions for OSCC patients. |
format | Online Article Text |
id | pubmed-9301677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93016772022-07-22 Risk Stratification in Oral Cancer: A Novel Approach Tu, Irene Wen-Hui Shannon, Nicholas Brian Thankappan, Krishnakumar Balasubramanian, Deepak Pillai, Vijay Shetty, Vivek Rangappa, Vidyabhushan Chandrasekhar, Naveen Hedne Kekatpure, Vikram Kuriakose, Moni Abraham Krishnamurthy, Arvind Mitra, Arun Pattatheyil, Arun Jain, Prateek Iyer, Subramania Subramaniam, Narayana Iyer, N. Gopalakrishna Front Oncol Oncology BACKGROUND: Oral squamous cell carcinoma (OSCC) is a common head and neck cancer with high morbidity and mortality. Currently, treatment decisions are guided by TNM staging, which omits important negative prognosticators such as lymphovascular invasion, perineural invasion (PNI), and histologic differentiation. We proposed nomogram models based on adverse pathological features to identify candidates suitable for treatment escalation within each risk group according to the National Comprehensive Cancer Network (NCCN) guidelines. METHODS: Anonymized clinicopathologic data of OSCC patients from 5 tertiary healthcare institutions in Asia were divided into 3 risk groups according to the NCCN guidelines. Within each risk group, nomograms were built to predict overall survival based on histologic differentiation, histologic margin involvement, depth of invasion (DOI), extranodal extension, PNI, lymphovascular, and bone invasion. Nomograms were internally validated with precision–recall analysis and the Kaplan–Meier survival analysis. RESULTS: Low-risk patients with positive pathological nodal involvement and/or positive PNI should be considered for adjuvant radiotherapy. Intermediate-risk patients with gross bone invasion may benefit from concurrent chemotherapy. High-risk patients with positive margins, high DOI, and a high composite score of histologic differentiation, PNI, and the American Joint Committee on Cancer (AJCC) 8th edition T staging should be considered for treatment escalation to experimental therapies in clinical trials. CONCLUSION: Nomograms built based on prognostic adverse pathological features can be used within each NCCN risk group to fine-tune treatment decisions for OSCC patients. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9301677/ /pubmed/35875164 http://dx.doi.org/10.3389/fonc.2022.836803 Text en Copyright © 2022 Tu, Shannon, Thankappan, Balasubramanian, Pillai, Shetty, Rangappa, Chandrasekhar, Kekatpure, Kuriakose, Krishnamurthy, Mitra, Pattatheyil, Jain, Iyer, Subramaniam and Iyer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tu, Irene Wen-Hui Shannon, Nicholas Brian Thankappan, Krishnakumar Balasubramanian, Deepak Pillai, Vijay Shetty, Vivek Rangappa, Vidyabhushan Chandrasekhar, Naveen Hedne Kekatpure, Vikram Kuriakose, Moni Abraham Krishnamurthy, Arvind Mitra, Arun Pattatheyil, Arun Jain, Prateek Iyer, Subramania Subramaniam, Narayana Iyer, N. Gopalakrishna Risk Stratification in Oral Cancer: A Novel Approach |
title | Risk Stratification in Oral Cancer: A Novel Approach |
title_full | Risk Stratification in Oral Cancer: A Novel Approach |
title_fullStr | Risk Stratification in Oral Cancer: A Novel Approach |
title_full_unstemmed | Risk Stratification in Oral Cancer: A Novel Approach |
title_short | Risk Stratification in Oral Cancer: A Novel Approach |
title_sort | risk stratification in oral cancer: a novel approach |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301677/ https://www.ncbi.nlm.nih.gov/pubmed/35875164 http://dx.doi.org/10.3389/fonc.2022.836803 |
work_keys_str_mv | AT tuirenewenhui riskstratificationinoralcanceranovelapproach AT shannonnicholasbrian riskstratificationinoralcanceranovelapproach AT thankappankrishnakumar riskstratificationinoralcanceranovelapproach AT balasubramaniandeepak riskstratificationinoralcanceranovelapproach AT pillaivijay riskstratificationinoralcanceranovelapproach AT shettyvivek riskstratificationinoralcanceranovelapproach AT rangappavidyabhushan riskstratificationinoralcanceranovelapproach AT chandrasekharnaveenhedne riskstratificationinoralcanceranovelapproach AT kekatpurevikram riskstratificationinoralcanceranovelapproach AT kuriakosemoniabraham riskstratificationinoralcanceranovelapproach AT krishnamurthyarvind riskstratificationinoralcanceranovelapproach AT mitraarun riskstratificationinoralcanceranovelapproach AT pattatheyilarun riskstratificationinoralcanceranovelapproach AT jainprateek riskstratificationinoralcanceranovelapproach AT iyersubramania riskstratificationinoralcanceranovelapproach AT subramaniamnarayana riskstratificationinoralcanceranovelapproach AT iyerngopalakrishna riskstratificationinoralcanceranovelapproach |